SOUTHPORT, Connecticut, September 6, 2006 -- Carter Morse & Mathias (“CM&M”) today announced that Opus Health, LLC (“ OPUS Health”), a leading provider of direct-to-patient persistence technologies to the pharmaceutical industry, has sold substantially all of its assets to Dendrite International, Inc. (NASDAQ: DRTE ). OPUS Health, a wholly-owned subsidiary of OCI Ventures, LLC, was founded in 1996 and is based in Hauppauge, NY. CM&M was OPUS Health’s exclusive financial advisor in arranging, structuring and negotiating the transaction.
The sale of OPUS Health to Dendrite enables the combined companies to provide the industry’s most complete end-to-end, multi-channel patient persistence solution, which links pharmaceutical companies, prescribers, pharmacies and patients. The tendency for patients to drop drug therapy, particularly for chronic conditions, is a far-reaching problem for all key healthcare constituents: patient, provider, payer, pharmaceutical/biotech manufacturer, pharmacy and government. With this transaction, Dendrite adds its breadth of marketing services around OPUS Health technology to deliver complete patient persistence programs and analysis.
OPUS Health will operate as a division of Dendrite within Dendrite’s Marketing Solutions business. Dendrite and OPUS Health have already collaborated in providing such programs for more than 40 pharmaceutical brands. This strategic acquisition reinforces Dendrite’s early lead as a provider of electronic direct-to-patient programs in the United States.
"Dendrite has always been an industry visionary and we are glad to be joining the Dendrite family,” said Harvey Brofman, a founder of OPUS Health and CEO of the company prior to its sale to Dendrite. "With the acquisition of OPUS Health into its Marketing Solutions group, Dendrite has a more powerful, streamlined solution in the area of patient persistence. We also believe that being part of Dendrite will enhance our product offering to partners and strengthen our relationships with them.” Mr. Brofman will serve as vice president and general manager of the OPUS Health group at Dendrite.
“The acquisition of OPUS Health is consistent with our strategy to be a leader in direct-to-patient persistence solutions,” said Carl Cohen, president of Dendrite Marketing Solutions. “Patients respond to the solution because of its ease of use, instant point-of-sale nature, and availability at their local pharmacies. Our customers and other healthcare constituents value the end-to-end nature of our programs, which improve patient health and help lower overall costs.”